In premenopausal women with gynecologic illness, Minodronic acid may prevent osteoporosis following oophorectomy independent of age at oophorectomy, adjuvant therapy, cancer type, or body mass index.

A single-centre, non-randomized controlled, experimental trial examined the effectiveness of Minodronic acid in preventing osteoporosis in premenopausal women who underwent bilateral oophorectomy for gynecologic illness.

For 101 individuals, data on bone alkaline phosphatase (BAP)/tartrate-resistant acid phosphatase 5 b (TRACP 5 b), young adult mean, and bone mineral density (BMD) from the femur and lumbar vertebrae were collected. The effectiveness of Minodronic acid in preventing osteoporosis was the major outcome ascertained. Overall, 55 and 31 subjects were allocated to medication and no medication groups, respectively.

In the medication group, the rise in BAP/TRACP-5b and the decline in young adult mean and BMD were markedly more repressed. Adjuvant treatment, body mass index (BMI), cancer type, age at oophorectomy did not differ significantly between groups. The use of Minodronic acid did not cause any adverse events.

The use of Minodronic acid is associated with a reduction in the rise in BAP/TRACP 5b and the decline in BMD and young adult mean in premenopausal women with gynecologic disease following oophorectomy.